Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.

Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone.

Imperagen, a UK-based deeptech, raised £5 million in seed funding led by PXN Ventures, with ongoing support from IQ Capital and Northern Gritstone.

The company's closed-loop platform is designed to dramatically speed up enzyme development for pharmaceuticals, sustainable chemicals and industrial biotech.